Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim has entered into a worldwide research and license collaboration with TransTech Pharma to discover and develop novel small molecules as therapeutics against an undisclosed biological target of interest to both companies.
Subscribe to our email newsletter
The collaboration will specifically use TransTech’s proprietary TTP translational technology. TransTech is set to receive up to $54 million in a combination of an upfront payment, research support and payments upon the achievement of specified research, clinical and commercialization milestones.
Meanwhile, Boehringer Ingelheim has the exclusive right to develop and commercialize all compounds directed at the target covered by the collaboration.
“The alliance with TransTech Pharma provides an innovative lead-finding technology to be combined with Boehringer Ingelheim’s strength in drug discovery. We look forward to rapidly exploring this technology to identify drug candidates for a highly relevant biologic target”, said Prof Mikael Dolsten, head of corporate division Pharma Research, Boehringer Ingelheim.
TransTech’s TTP translational technology is a highly automated drug discovery process including proprietary software modules. The technology already has shown to work effectively against a wide range of biological targets including protein-protein interactions, receptor modulators and enzyme inhibitors, and delivered small-molecule-based preclinical and clinical drug candidates for the treatment of diabetes, cancer, inflammation, Alzheimer’s disease and thrombosis.